Product Description
Erlotinib is used to treat certain types of non-small cell lung cancer that has spread to nearby tissues or to other parts of the body in patients who have already been treated with at least one other chemotherapy medication and have not gotten better. Erlotinib is also used in combination with another medication (gemcitabine [Gemzar]) to treat pancreatic cancer that has spread to nearby tissues or to other parts of the body and cannot be treated with surgery. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a605008.html)
Mechanisms of Action: EGFR Inhibitor,TK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Kazakhstan, Korea, Latvia, Mexico, Netherlands, Norway, Peru, Poland, Portugal, Romania, Saudi Arabia, Spain, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 19
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer
Phase 2: Abnormalities, Multiple|Biliary Tract Cancer|Bladder Cancer|Breast Cancer|Clear Cell Sarcoma|Hepatocellular Carcinoma|Hodgkin Lymphoma|Intestinal Cancer|Liver Cancer|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Multiple Myeloma|Oncology Solid Tumor Unspecified|Oncology Unspecified|Renal Cell Carcinoma|Vision, Low
Phase 1: Gastrointestinal Cancer|Kidney Cancer|Kidney Diseases|Mouth Cancer|Pregnancy Outcomes|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DRUP | P2 |
Recruiting |
Lymphoma, B-Cell|Abnormalities, Multiple|Lymphoma, Non-Hodgkin|Vision, Low|Hodgkin Lymphoma|Multiple Myeloma |
2027-09-01 |
|
| BRISK | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2025-01-31 |
|
| IRX4204 NSCLC 1 01 2015 | P1 |
Suspended |
Non-Small-Cell Lung Cancer |
2024-12-31 |
27% |
| IRX4204 NSCLC 1 01 2015 | P1 |
Suspended |
Non-Small-Cell Lung Cancer |
2024-12-31 |
27% |
| EGFR | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
2024-12-31 |
57% |
| EGFR | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
2024-12-31 |
57% |
| EGFR | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
2024-12-31 |
57% |